Guvenoz v. Target Corp.
30 N.E.3d 404
Ill. App. Ct.2015Background
- Plaintiff Nicole Guvenoz (as representative of Lewis Guvenoz’s estate) sued generic manufacturer Teva and retailer/distributor Target after Lewis suffered cardiac arrest and later died following prescribed propoxyphene (Darvocet) use; complaint alleges the drug was ineffective and carried unreasonably high cardiac risks.
- Complaint (post-Mensing, pre-Bartlett) pleads negligence, strict product liability/design defect, fraudulent misrepresentation, fraudulent concealment, and Illinois Consumer Fraud Act claims against Teva and Target.
- Defendants moved to dismiss under Ill. R. 2-615/2-619, principally arguing federal preemption under the Supreme Court’s Mensing/Bartlett line of cases; the trial court denied dismissal and certified legal questions under Ill. S. Ct. R. 308.
- The core legal dispute: whether state-law claims against a generic manufacturer/distributor for marketing an allegedly unreasonably dangerous drug are preempted by federal law requiring generic labels/design to match the brand (pre-2007 framework as treated in Mensing/Bartlett).
- The appellate court accepts plaintiffs’ well-pled allegations as true for this interlocutory, purely legal review and frames its answers to whether categories of Illinois causes of action can survive federal preemption given Mensing/Bartlett.
Issues
| Issue | Plaintiff's Argument | Defendant's Argument | Held |
|---|---|---|---|
| Negligence (design/manufacture/distribution) | Guvenoz: defendants marketed an unsafe, ineffective drug and breached duties; claim does not rely on altering label/design. | Teva/Target: federal law (Mensing/Bartlett) preempts state negligence claims because generics cannot change label/design. | Court: Not preempted — plaintiff alleges the drug should not have been sold; claims do not depend on changing federally-mandated sameness. |
| Strict liability / design defect | Guvenoz: product failed consumer-expectation and fails risk-utility — risks outweigh any marginal benefit. | Defendants: Bartlett/Mensing preempt design-defect claims because federal duties bar altering design or warnings. | Court: Not preempted — where no practicable remedial measure (only withdrawal suffices), Bartlett/Mensing logic does not bar strict-liability claims. |
| Fraudulent misrepresentation / fraudulent concealment | Guvenoz: marketing the drug as safe/effective was an actionable misrepresentation/half-truth; concealment actionable because defendants had superior knowledge. | Defendants: Any actionable statement would conflict with federal duty of sameness and thus be preempted. | Court: Not preempted — claims allege affirmative misrepresentation/marketing of a useless, risky product, not merely a failure-to-warn that would require label change. |
| Illinois Consumer Fraud Act claim | Guvenoz: deceptive acts, omissions, misrepresentations in trade/commerce; consumer-protection statute claims not premised on label-change authority. | Defendants: CFA claim is functionally preempted under Mensing/Bartlett. | Court: Not preempted — statutory deceptive-practices claim based on marketing/omission survives for same reasons as fraud claims. |
Key Cases Cited
- Wyeth v. Levine, 555 U.S. 555 (2009) (pre-emption is disfavored; Congress did not plainly occupy the field; manufacturers bear burden to show impossibility).
- Medtronic, Inc. v. Lohr, 518 U.S. 470 (1996) (purpose of Congress is ultimate touchstone for pre-emption analysis).
- Freightliner Corp. v. Myrick, 514 U.S. 280 (1995) (impossibility pre-emption arises when compliance with both federal and state obligations is impossible).
- English v. General Electric Co., 496 U.S. 72 (1990) (pre-emption analysis and impossibility framework).
- Calles v. Scripto-Tokai Corp., 224 Ill. 2d 247 (2007) (elements and standards for negligence and strict liability/design-defect under Illinois law).
- Jablonski v. Ford Motor Co., 2011 IL 110096 (2011) (Illinois risk-utility and consumer-expectation tests for strict liability).